. Author manuscript; available in PMC: 2011 Sep 1.

Published in final edited form as: Curr Opin HIV AIDS. 2010 Sep;5(5):428–434. doi: 10.1097/COH.0b013e32833d17ac

Table 2. Proposed post RV144 clinical development pathway and priorities.

Short-term strategy	Long-term strategy
Understanding what happened, identifying a correlate, and improving the vaccine	Advancing the result, optimizing the regimen for other populations

RV144 laboratory studies to identify an immune correlate of protection

Late boosting study of RV144 vaccinated volunteers	Phase IIB efficacy study of RV144 regimen in a clade E (Thai) (high vs. low incidence), heterosexual vs. men who have sex with men populations.

Immunogenicity study reproducing the RV144 regimen with different boosting options	Phase IIB efficacy study in a non-clade E, higher-incidence population (clade-matched antigens)

Improvements and additional Phase I exploratory studies: ALVAC, other pox vector such as NYVAC and possible new boost, insert, adjuvant; heterologous prime-boost regimens with new vectors and inserts (adenovirus, MVA, mosaics)

Cohort development in relevant populations